Protocol Ledger

NCT04608630 · Phase II · RECRUITING

Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

Interventional Phase II clinical trial protocol NCT04608630 sponsored by Australian and New Zealand Intensive Care Research Centre in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-07-15 Enrollment: 450 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04608630
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)450 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04608630
Protocol FieldVerified Registry Value
NCT IdentifierNCT04608630
Consolidated Lead SponsorAustralian and New Zealand Intensive Care Research Centre
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment450 participants (ESTIMATED)
Registered Start Date2021-07-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04608630
Hospital Research SiteLocationSite Profile
Sunshine Coast University HospitalBirtinya, AustraliaOpen Hospital Dossier ->
Royal Adelaide HospitalAdelaide, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI